Fibroid treatment with ulipristal acetate resulted in a significant improvement of fibroid-related symptoms; moreover, it proved to be effective in decreasing both uterine and fibroid volumes and fibroid vascularization. Type 5 fibroids seem to have the most major response to treatment.

CffDNA, from 344 non-smoking, 38 smoking and 33 ex-smoking pregnant women at 11 (+0)-13 (+6) gestational weeks, was extracted and quantified by the multicopy DYS14, as the fetal DNA marker and using the quantitative real-time PCR 7300 detection system. The smoking habit was based on maternal self-report, confirmed by cotinine levels and male fetuses were verified by phenotype at birth. The genders of newborns were compared with DYS14-cffDNA analysis, achieving a 100% diagnostic accuracy of the test. A total of 177 non-smokers, 18 smokers and 22 ex-smoker pregnancies with male fetuses were identified by the cffDNA concentration. Results showed that smoking status was not associated with different amounts of DYS14-cffDNA (p = 0.159), suggesting the possibility of offering cffDNA testing to all pregnant women, even if they are active smokers or ex-smokers, and the test can be unadjusted for smoking status.

Background: This study assessed the diagnostic accuracy of a non-invasive approach to fetal RHD genotyping using cell-free fetal DNA in maternal plasma and a combination of methodological strategies. Methods: Real-time PCR (qPCR) was performed on 216 RhD-negative women between weeks 10+0 and 14+6 of gestation (1st qPCR). qPCR was repeated (2nd qPCR) to increase the amount of each sample for analysis, on 95 plasma aliquots that were available from first trimester blood collection (group 1) and on 13 samples that were collected between weeks 18+0 and 25+6 of gestation (group 2). qPCR was specific for exons 5 and 7 of the RHD gene (RHD5 and RHD7). The results were interpreted according to the number of positive replicates of both exons. Results: 1st qPCR: diagnostic accuracy was of 93.3%. Diagnostic accuracy increased from 90.5% (1st qPCR) to 93.7% (2nd qPCR) in group 1 and from 84.6% (1st qPCR) to 92.3% (2nd qPCR) in group 2. These increments were not statistically significant. Conclusion: Our approach to RHD genotyping in early pregnancy yielded high diagnostic accuracy. Increasing the amount of DNA analyzed in each sample did not improve significantly the diagnostic accuracy of the test.

No abstract

Electronic poster abstractsBackground: Clinical symptom of fibroid uterus can be varying from menorrhagia, pain, subfertility and altered bowel and bladder symptoms. Thrombosis is rare complication of fibroid uterus.Case review: 47 year old women referred to the A & E with history of Dyspnoea, weight loss, loss of appetite and abdominal distention. O/E Women with large abdominal mass which equivalent to nearly 36 POA.Hb 3g/dl 2D Echo done-Pericardial Effusion+ Duplex Studies -Non occlusive thrombus within the left femoral and popliteal veins CT Scan-Massive abdomino pelvic solid mass USS Guided Bx-benign leiomyom MRI -Heterogeneous mass in the abdomen and Pelvis probably arising from the uterus. The patient start on therapeutic Tinzaparin for DVT for 6 weeks. Laparotomy done under the Gyne care.IVC filters inserted to decrease the risk of perioperative pulmonary embolism. Large fibroid uterus with multiple pedunculate fibroids noted. Whole fibroid uterus removed as one mass. Weight of the specimen 16.8Kg Discussion. Due to huge fibroid mass there are more stasis of blood in the vascular system which leads to thromboembolism. Uterine leiomyoma usually developed in women with compressive pelvic veins, contributing to pelvic and lower limb thrombosis with the left leg more commonly affected. These conditions usually treat using anticoagulant and or thrombosis along with hysterectomy. Conclusion-Although DVT associate with uterine myoma are rare event, it can be managed successfully with hysterectomy after anticoagulant therapy.Supporting information can be found in the online version of this abstract EP28.06 Survey on selecting patients with postmenopausal bleeding (PMB) for hysteroscopy: current practice and future clinical effectiveness. E. Zielinski, C. Gnanachandran Obstetrics and Gynecology, Northampton General Hospital NHS Trust, Northampton, United KingdomObjectives: There is robust evidence for endometrial biopsy for PMB when endometrial thickness is above 3mm/5mm. However, there is a lack of evidence for hysteroscopic visualisation of the endometrium before biopsy. This study aimed to understand the variation in clinical practice regarding hysteroscopy for PMB, and to improve clinical effectiveness in investigations for patients with PMB. Methods: Questionnaire among BSGE and BGCS members involved in PMB patient care regarding current practices of investigation. Results: 286 members involved in managing PMB responded. 189 responses were from consultant level and 49 from nurse practitioners. There is a variation in minimum thickness for endometrial biopsy from 3 mm to 5mm. However, 25 responders said endometrial biopsy was performed regardless of endometrial thickness. There is also significant disparity regarding when hysteroscopy should be done. 53% of respondents would like to have a cut-off for hysteroscopy even though suggested values varied.In a large number of units, PMB scans are done by sonographers, however more than 75% of responders reported that there was no clinical governance for quality of o...